ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1999

Magnetic Resonance Imaging of Skeletal Muscles in Patients with Dermatomyositis and Polymyositis: Novel and Distinctive Characteristic Findings

Taro Ukichi1, Ken Yoshida1, Satoshi Matsushima2, Go Kawakami2, Kentaro Noda1, Kazuhiro Furuya1 and Daitaro Kurosaka1, 1Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, 2Department of Radiology, Jikei University School of Medicine, Tokyo, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, autoimmune diseases, magnetic resonance imaging (MRI) and polymyositis/dermatomyositis (PM/DM)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Imaging of Rheumatic Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Radiological studies to distinguish between dermatomyositis (DM) and polymyositis (PM) are few. We predicted that the magnetic resonance imaging (MRI) findings of skeletal muscle would differ between DM and PM because of the differences in the histopathological findings associated with the disorders. Our objective was to establish distinctive MRI characteristics of skeletal muscle in patients with DM or PM.

Methods: The MRI findings (short-tau inversion recovery [STIR] and gadolinium-enhanced fat-suppressed T1-weighted imaging [Gd-T1WI]) of proximal limb skeletal muscles in patients with DM (n = 53) or PM (n = 32) were evaluated. Differences in the percentage appearances of the following findings in the axial plane between DM and PM patients and between autoantibody-positive and autoantibody-negative PM patients were analyzed: structures with high signal intensity (HSI) (subcutaneous adipose tissue, fascia, muscle); distributions of HSI areas in muscle (diffuse, patchy, peripheral); patterns of HSI in muscle (honeycomb, foggy, strong high signal intensity [SHSI] ).

Results: Among the 79 patients with abnormal MRI findings, 48 were diagnosed with DM and 31 were diagnosed with PM. Of these, Gd-T1WI was performed in 45 patients with DM and 27 patients with PM. Table 1 shows the differences in the percentage appearances of MRI findings between DM and PM patients. On STIR and Gd-T1WI images, the percentage appearances of the following characteristics were higher in DM patients than in PM patients: subcutaneous HSI, fascial HSI, peripheral distribution in muscle, honeycomb pattern in muscle. Patchy distribution and foggy pattern in muscle were higher in PM patients than in DM patients. There were no significant differences between the groups for diffuse distribution and SHSI pattern in muscle. Table 2 shows the differences in the percentage appearances of MRI findings between the autoantibody-positive and autoantibody-negative PM groups. The percentage appearances of subcutaneous and fascial HSI on STIR and Gd-T1WI images were higher in autoantibody-positive PM patients than in autoantibody-negative PM patients. Patchy distribution in muscle on Gd-T1WI was higher in autoantibody-negative PM patients than in autoantibody-positive PM patients.

Conclusion: Subcutaneous and fascial HSI, peripheral distribution in muscle, and honeycomb pattern in muscle are characteristic MRI findings in patients with DM, whereas patchy distribution and foggy pattern in muscle are characteristic MRI findings in patients with PM. MRI could be a useful tool for diagnosing DM and PM.


Table 1: Percentage appearances of characteristic findings on MRI in patients with DM or PM*
STIR DM ( n = 48 ) PM ( n = 31 ) p-value†
subcutaneous HSI 34 (70.8) 9 (29.0) <0.001
fascial HSI 41 (85.4) 13 (41.9) <0.001
peripheral distribution 43 (89.6) 14 (45.2) <0.001
diffuse distribution 23 (47.9) 14 (45.2) 0.81
patchy distribution 12 (22.9) 15 (48.4) <0.05
honeycomb pattern 34 (70.8) 11 (35.5) <0.01
foggy pattern 3 (6.3) 17 (54.8) <0.001
SHSI pattern 9 (18.8) 2 (6.5) 0.12
Gd-T1WI DM ( n = 45 ) PM ( n = 27 ) p-value†
subcutaneous HSI 31 (68.9) 8 (29.6) <0.01
fascial HSI 37 (82.2) 10 (37.0) <0.001
peripheral distribution 40 (88.9) 12 (44.4) <0.001
diffuse distribution 20 (44.4) 9 (33.3) 0.35
patchy distribution 10 (22.2) 16 (59.3) <0.01
honeycomb pattern 34 (75.6) 7 (25.9) <0.001
foggy pattern 3 (6.7) 13 (48.1) <0.001
SHSI pattern 6 (13.3) 2 (7.4) 0.44

* Values are the number (%).

† Statistical analysis was performed by Pearson’s chi-square test.


Table 2: Percentage appearances of characteristic findings on MRI in autoantibody-positive and autoantibody-negative PM groups*
STIR AA (+) ( n = 18 ) AA (-) ( n = 13 ) p-value†
subcutaneous HSI 8 (44.4) 1 (7.7) <0.05
fascial HSI 13 (72.2) 0 (0.0) <0.001
peripheral distribution 8 (44.4) 5 (38.5) 1.00
diffuse distribution 8 (44.4) 6 (46.2) 1.00
patchy distribution 6 (33.3) 9 (69.2) 0.073
honeycomb pattern 9 (50.0) 2 (15.4) 0.066
foggy pattern 7 (38.9) 10 (76.9) 0.067
SHSI pattern 1 (5.6) 1 (7.7) 1.00
Gd-T1WI AA (+) ( n = 15 ) AA (-) ( n = 12 ) p-value†
subcutaneous HSI 7 (46.7) 1 (8.3) <0.05
fascial HSI 10 (66.7) 0 (0.0) <0.001
peripheral distribution 7 (46.7) 5 (41.7) 1.00
diffuse distribution 6 (40.0) 3 (25.0) 0.68
patchy distribution 6 (40.0) 10 (83.3) <0.05
honeycomb pattern 6 (40.0) 1 (8.3) 0.091
foggy pattern 5 (33.3) 8 (66.7) 0.13
SHSI pattern 1 (6.7) 1 (8.3) 1.00

* Values are the number (%). AA (+) = an autoantibody-positive PM group, containing patients with myositis-specific autoantibodies, myositis-associated autoantibodies, and/or other connective tissue disease-specific autoantibodies; AA (-) = an autoantibody-negative PM group, containing patients without these autoantibodies.

† Statistical analysis was performed by Fisher’s exact test.



Disclosure: T. Ukichi, None; K. Yoshida, None; S. Matsushima, None; G. Kawakami, None; K. Noda, None; K. Furuya, None; D. Kurosaka, None.

To cite this abstract in AMA style:

Ukichi T, Yoshida K, Matsushima S, Kawakami G, Noda K, Furuya K, Kurosaka D. Magnetic Resonance Imaging of Skeletal Muscles in Patients with Dermatomyositis and Polymyositis: Novel and Distinctive Characteristic Findings [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/magnetic-resonance-imaging-of-skeletal-muscles-in-patients-with-dermatomyositis-and-polymyositis-novel-and-distinctive-characteristic-findings/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/magnetic-resonance-imaging-of-skeletal-muscles-in-patients-with-dermatomyositis-and-polymyositis-novel-and-distinctive-characteristic-findings/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology